Personalis, Inc. (PSNL) Stock Price & Analysis
Personalis, Inc. (PSNL) fell 3.60% to USD 11.78 as of July 25, 2026 at 08:27 UTC, according to Nexqual real-time market data.
PSNL last closed at USD 12.22; the session ranged USD 11.74–12.63 on volume of 2,825,889 shares. Market capitalization is $1.26B, with a 52-week range of USD 3.84–16.39 (NGM). Source: Nexqual, July 25, 2026 at 08:27 UTC.
Key Statistics (as of July 25, 2026 at 08:27 UTC)
| Price | USD 11.78 |
|---|---|
| Change | ▼ 3.60% (down) |
| Previous Close | USD 12.22 |
| Open | USD 12.34 |
| Day Range | USD 11.74 – 12.63 |
| 52-Week Range | USD 3.84 – 16.39 |
| Volume | 2,825,889 shares |
| Market Cap | $1.26B |
| Exchange | NGM |
Technical Analysis (PSNL)
Nexqual's technical model rates PSNL "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 08:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 40.15 (neutral) |
| vs SMA50 | Above (USD 11.32) |
| MACD | 0.45 (positive) |
Analyst Ratings (PSNL)
Wall Street analysts rate PSNL "Buy" based on 4 analysts, with a mean price target of USD 13.88 (range USD 10–16.25), per Nexqual as of July 25, 2026 at 08:27 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 13.88 |
| High Target | USD 16.25 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 4 / 2 / 0 |
Earnings (PSNL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.28 |
| Revenue Estimate | $16.79M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.29 vs est -0.28 ▼ miss |
| 2025-12-31 | USD -0.26 vs est -0.29 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.27 ▲ beat |
| 2025-06-30 | USD -0.23 vs est -0.24 ▲ beat |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Financials & Fundamentals (PSNL)
| Total Revenue | $64.52M |
|---|---|
| Revenue Growth (YoY) | -24.90% |
| Gross Margin | +13.72% |
| Operating Margin | -207.87% |
| Profit Margin | -148.11% |
| ROE | -41.35% |
| Debt / Equity | 15.22 |
| Current Ratio | 6.61 |
| Total Cash | $233.22M |
| Total Debt | $38.78M |
| Free Cash Flow | $-42.35M |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Financial Health Score (PSNL)
Nexqual rates Personalis, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 08:27 UTC.
| Growth | Critical — Revenue -18% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $233M cash vs $39M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$42M, burning cash |
| Efficiency | Critical — ROE -41%, ROA -21.4% |
Ownership (PSNL)
| Insider Ownership | +26.16% |
|---|---|
| Institutional Ownership | +67.03% |
| Shares Outstanding | 106.75M |
| Float | 64.49M |
| Short % of Float | +16.74% |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Leadership (PSNL)
Personalis, Inc. is led by Christopher M. Hall (age 56), CEO & Director, per Nexqual as of July 25, 2026 at 08:27 UTC.
| CEO & Director | Christopher M. Hall (age 56) |
|---|---|
| CFO & COO | Aaron L. Tachibana (age 64) |
| Senior Vice President of Genomic Science | Christian Haudenschild |
| Senior Vice President of Business Development | Stephane Mouradian |
| Senior Vice President of Regulatory, Quality & Clinical Compliance | Deepshikha Bhandari |
Major Backers & Investors (PSNL)
Notable institutional backers of Personalis, Inc. include ARK Invest, Merck & Co., Inc., Lightspeed Management Company, L.L.C. , according to Nexqual as of July 25, 2026 at 08:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 15.1% |
| Merck & Co., Inc. | 13.41% |
| Lightspeed Management Company, L.L.C. | 7.79% |
| T. Rowe Price | 7.51% |
| Ameriprise Financial, Inc. | 7.25% |
| Aberdeen Group plc | 3.33% |
| Deep Track Capital, Lp | 2.86% |
| AIGH Capital Management LLC | 2.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.31% |
| Vanguard Group | 4.83% |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
From Personalis, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
- The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
- It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.
- In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDNA | CareDx, Inc. | USD 37.14 | ▼ 1.69% |
| TWST | Twist Bioscience Corporation | USD 90.27 | ▼ 4.18% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| CSTL | Castle Biosciences, Inc. | USD 24.69 | ▼ 0.5% |
| ARCT | Arcturus Therapeutics Holdings | USD 5.53 | ▼ 6.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:27 UTC. This page is informational and not investment advice.